Evelo Biosciences, Inc. Quarterly Depreciation in USD from Q1 2017 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Evelo Biosciences, Inc. quarterly/annual Depreciation history and growth rate from Q1 2017 to Q3 2023.
  • Evelo Biosciences, Inc. Depreciation for the quarter ending September 30, 2023 was $200K, a 60% decline year-over-year.
  • Evelo Biosciences, Inc. Depreciation for the twelve months ending September 30, 2023 was $1.59M, a 24.3% decline year-over-year.
  • Evelo Biosciences, Inc. annual Depreciation for 2022 was $2.06M, a 7.04% decline from 2021.
  • Evelo Biosciences, Inc. annual Depreciation for 2021 was $2.22M, a 9.38% increase from 2020.
  • Evelo Biosciences, Inc. annual Depreciation for 2020 was $2.03M, a 14.9% increase from 2019.
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 $1.59M $200K -$300K -60% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $1.89M $400K -$100K -20% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $1.99M $445K -$72K -13.9% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-15
Q4 2022 $2.06M $543K -$37K -6.38% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-16
Q3 2022 $2.1M $500K -$100K -16.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $2.2M $500K $0 0% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $2.2M $517K -$19K -3.55% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 $2.22M $580K +$45K +8.41% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-16
Q3 2021 $2.17M $600K +$100K +20% Jul 1, 2021 Sep 30, 2021 10-Q/A 2021-10-29
Q2 2021 $2.07M $500K $0 0% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $2.07M $536K +$45K +9.17% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $2.03M $535K +$46K +9.41% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-24
Q3 2020 $1.98M $500K $0 0% Jul 1, 2020 Sep 30, 2020 10-Q/A 2021-10-29
Q2 2020 $1.98M $500K +$100K +25% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-29
Q1 2020 $1.88M $491K +$116K +30.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-29
Q4 2019 $1.76M $489K +$139K +39.7% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-09
Q3 2019 $1.63M $500K +$200K +66.7% Jul 1, 2019 Sep 30, 2019 10-Q 2020-10-30
Q2 2019 $1.43M $400K -$300K -42.9% Apr 1, 2019 Jun 30, 2019 10-Q 2020-07-31
Q1 2019 $1.73M $375K -$210K -35.9% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 $1.94M $350K +$79K +29.2% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-14
Q3 2018 $1.86M $300K +$100K +50% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-05
Q2 2018 $1.76M $700K +$500K +250% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 $1.26M $585K +$422K +259% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-03
Q4 2017 $834K $271K Oct 1, 2017 Dec 31, 2017 10-K 2020-02-14
Q3 2017 $200K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-02
Q2 2017 $200K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 $163K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.